MIRMMirum Pharmaceuticals, Inc.
Pharmaceutical Preparations
- Revenue
- $521M
- 55% YoY
- Operating margin
- -4.2%
- 84% YoY
- EBITDA
- $2M
- 103% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired14% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $19M | $77M | $186M | $337M | $521M | 55% |
| Operating income | −$173M | −$131M | −$109M | −$88M | −$22M | 75% |
| Net income | −$84M | −$136M | −$163M | −$88M | −$23M | 73% |
| Operating cash flow | −$133M | −$120M | −$71M | $10M | $56M | 441% |
| Capex | $24K | $278K | $109K | $993K | $954K | 3.9% |
| Stock-based comp | $23M | $27M | $35M | $48M | $71M | 47% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $4M · 4
- Net
- −$4M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $10M | $30M | 495 | 125 |
| FY2024 | $7M | $13M | 259 | 93 |
| FY2023 | $6M | $9M | 185 | 94 |
| FY2022 | $4M | $7M | 122 | 90 |